Stock Financial Ratios, Dividends, Split History
EYEG / Eyegate Pharmaceuticals Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||9.84|
|Enterprise Value ($M)||2.22|
|Book Value ($M)||-1.93|
|Book Value / Share||-0.11|
|Price / Book||-5.20|
|NCAV / Share||-0.45|
|Price / NCAV||-1.27|
|Income Statement (mra) ($M)|
|Balance Sheet (mrq) ($M)|
|Cash & Equivalents||7.81|
|Cash / Share||0.45|
|Common Shares Outstanding||17,257,255|
|Common Stock Shares Outstanding||17,257,255|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Cash Conversion Cycle||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||6.86|
|Return on Assets (ROA)||-1.36|
|Return on Equity (ROE)||40.12|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1372514|
|SIC 2834 - Pharmaceutical Preparations|
Stock splits are used by Eyegate Pharmaceuticals Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
Peers - Pharmaceutical Preparations (2834)
ADMP / Adamis Pharmaceuticals Corp.
ARGS / Argos Therapeutics, Inc.
BSPM / Biostar Pharmaceuticals, Inc.
CAPR / Capricor Therapeutics, Inc.
CRBP / Corbus Pharmaceuticals Holdings, Inc.
CTRV / Contravir Pharmaceuticals Inc
CWBR / CohBar Inc.
DFFN / Diffusion Pharmaceuticals Inc.
EDNV / ENDONOVO THERAPEUTICS, INC.
11h - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
12h - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...
Related News Stories
Intercept Pharmaceuticals (ICPT) reported clinical data from a liver biopsy-based substudy from its phase 3 POISE study. The study indicated that long-term OCA treatment in patients with PBC led to reversal or stabilization of fibrosis and cirrhosis. (143-3)
April 13, 2018: Here are four stocks trading with heavy volume among 52 equities making new 52-week lows in Friday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners led advancers by about 9 to 5. (19-0)
Today we will discuss Acadia Pharmaceuticals (NASDAQ:ACAD), which has fallen sharply on a CNN report that raised concerns about the Nuplazid’s safety. (210-3)
Incyte (NASDAQ:INCY) shares tumbled more than 17% as investors digested the disappointing news with regard to the company’s phase 3 study evaluating the Epacadostat/Keytruda combination in patients with unresectable or metastatic melanoma. (154-0)
* EYEGATE PHARMA SUBMITS INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL (12-1)
as of ET